Provisional NICE nod for Ilumetri

11 March 2019

Ilumetri (tildrakizumab), a humanized, high-affinity interleukin (IL)-23p19 monoclonal antibody from Spanish drugmaker Almirall (BME: ALM), has been recommended by the UK's National Institute for Health and Care Excellence (NICE) for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Following a single health technology assessment submission to the NICE in August 2018 and the subsequent questions for clarification and appraisal committee meetings, the UK’s cost-effectiveness watchdog has completed its assessment and has now issued a Final Appraisal Determination (FAD) provisionally recommending Ilumetri as a cost-effective treatment option for the National Health Service for the patients specified in the FAD. Final NICE approval is expected in April 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK